Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oculopharyngeal Muscular Dystrophy: early-phase trial registry
1 of 1 indexed Oculopharyngeal Muscular Dystrophy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Oculopharyngeal Muscular Dystrophy: 1 US clinical trial tracked, 1 recruiting.
Oculopharyngeal Muscular Dystrophy is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Benitec Biopharma, running 1 of these trials.
Enrollment posture brief
Registry condition oculopharyngeal-muscular-dystrophy
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Oculopharyngeal Muscular Dystrophy lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oculopharyngeal Muscular Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oculopharyngeal Muscular Dystrophy is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Oculopharyngeal Muscular Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oculopharyngeal Muscular Dystrophy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oculopharyngeal Muscular Dystrophy page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Oculopharyngeal Muscular Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Benitec Biopharma sponsors the most Oculopharyngeal Muscular Dystrophy trials on record, review their full trial history before evaluating a specific study. See Benitec Biopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oculopharyngeal Muscular Dystrophy condition card totals 1 registered trials; most-linked intervention BB-301: Dose expansion phase 2a; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.